You Position: Home > Paper

Pharmacotherapies for non-alcoholic steatohepatitis

( views:13, downloads:0 )
Author:
No author available
Journal Title:
World Chinese Journal of Digestology
Issue:
18
DOI:
10.11569/wcjd.v25.i18.1645
Key Word:
非酒精性脂肪肝病;非酒精性脂肪性肝炎;治疗;法尼酯X受体;胰高血糖素样肽-1;活性氧;Non-alcoholic fatty liver disease;Non-alcoholic steatohepatitis;Therapy;Farnesoid X receptor;Glucagon-like peptide agonist;Reactive oxygen species

Abstract: Non-alcoholic steatohepatitis (NASH),the more aggressive form of non-alcoholic fatty liver disease,may progress to cirrhosis and hepatocellular carcinoma.Only changes in diet and lifestyle are hard to maintain and have little effect in delaying the progression of NASH.Traditional methods are effective in reducing steatosis and inflammation,but they have no effect on fibrosis,which is the main determinant of patient outcome.With the understanding of the pathogenesis and progression of NASH,several promising novel therapies to target and possibly reverse fibrosis are being evaluated,making the future of NASH therapy more optimistic.

WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn